, China
/Geralt from Pixabay

PICC P&C posts mixed Q1’24 results, eyes stability

Even with a 5% QoQ improvement in investment income, it still saw a 36% YoY decline.

Despite PICC Property and Casualty Co.’s (PICC P&C) earnings miss mainly attributed to weaker-than-expected investment performance, management reaffirmed its commitment to shareholder returns amid near-term volatility, a Jefferies research report said.

PICC P&C reported a 1Q’24 net profit of Rmb5.9b, marking a -38% year-on-year (YoY) decrease but a 13% quarter-on-quarter (QoQ) increase, falling notably short of market expectations. 

The combined ratio (CoR) rose by 2.2 percentage points YoY to 97.9%, mainly due to adverse weather during the Chinese New Year. 

ALSO READ: S&P predicts modest capital upkeep for PICC Group amidst market changes

Despite a 5% QoQ improvement in investment income, including associates, it still saw a significant 36% YoY decline, impacting profit growth. 

Core solvency fell by 1.8 percentage points QoQ to 206.9%.

Key negatives include the increased CoR and underwriting profit decline, partly due to the impact of natural catastrophes. 

However, there are positives such as insurance revenue growth (+6% year-on-year, +2% quarter-on-quarter), exceeding market expectations. 

Follow the link for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.